Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "Rhinovirus infection" patented technology

Rhinovirus infection: Introduction. Rhinovirus infection: Infection with the rhinovirus which can be transmitted through direct contact with contaminated secretions from an infected person (e.g. sneezing or nasal or oral secretions on hands).

Modified fluorinated nucleoside analogues

The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.
Owner:GILEAD SCI INC

Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections

Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and / or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.
Owner:RESPIVERT

Methods for Detecting and Treating Rhinovirus Infection

The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.
Owner:THE PROCTER & GAMBLE COMPANY

Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan

InactiveUS20080131454A1Easily incorporated into tissue materialPrevent and reduce riskOrganic active ingredientsBiocideCarrageenanAntiviral drug
The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.
Owner:MARINOMED BIOTECHNOLOGIE GMBH

Method for detecting rhinovirus typing and enterovirus

The invention provides a method for rapidly detecting HRV typing and EV by single-tube multiplex-RT-PCR. The method comprises the following steps: a) collecting a sample; b) extracting nucleic acid from the sample; c) adding the extracted nucleic acid to a premixed RT-PCR reagent; d) running an RT-PCR amplification program; and e) performing fragment analysis on the obtained RT-PCR amplification product, wherein the premixed RT-PCR reagent contains a primer specifically for HRV typing and a primer specifically for EV. The method has the advantages of simplicity in operation, short time and high flux, so a result can be obtained in 4 h at the soonest, and the method is suitable for clinic detection and scientific researches. The HRV virus typing result detected by the method can be used forguiding clinicians to medicate, and also can be used for the pathological study of rhinovirus infection.
Owner:NINGBO HEALTH GENE TECHNOLOGIES CO LTD

Use of medicine for treating virus infection of respiratory system

The invention relates to a method for producing drug that treats virus infection of respiratory tract, wherein it uses Arbidol Hydrochloride as 6-bromine-4-(dimethylamino)-5-hydroxyl group-1-methyl-2-(benzene sulfenyl)-1H-indole-3-glycolate-hydrates. The invention can reduce the mouse dead rate affected by virus B3, B5, adenovirus, etc, and improve antibody level, with wide application.
Owner:WUHAN UNIV

Application of recombinant alpha-interferon in preparing medicine for preventing and treating respiratory system infection

The alpha-interferon has been used mainly in treating chronic viral infection. The present invention uses coronavirus or rhinovirus infected human cervical cancer cell as estimation model in observing the inhibition effect of alpha-interferon on common virus causing respiratory system infection. The results show that alpha-interferon may be used in preventing and treating coronavirus and rhinovirus caused diseases, including SARS. The integrated interferon, its mutant and interferon alpha-1b have even high inhibiting effect on new SARS virus.
Owner:BEIJING TRI PRIME GENE PHARMA CO LTD +1

Nitric oxide inhibits rhinovirus infection

Nitric oxide generating compounds or compounds which induce in situ synthesis of nitric oxide can be used to inhibit rhinovirus infection. Nitric oxide has the ability to inhibit both viral replication as well as the synthesis of cytokines, in particular the proinflammatory cytokines. Thus the symptoms of rhinovirus infections can be ameliorated by treatments to increase nitric oxide in the respiratory tract.
Owner:THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Treatment of respiratory infection with a tlr2 agonist

The present invention relates to methods, compositions and kits for the treatment or prevention of respiratory conditions. In particular, the methods, compositions and kits are particularly useful, but not limited to, the prevention and / or treatment of rhinovirus infection and the prevention and / or treatment of asthma exacerbation. The invention provides a method inhibiting a rhinovirus infection in a subject comprising administering a composition consisting of a compound comprising a TLR2 agonist and a pharmaceutically acceptable carrier.
Owner:ENA RESPIRATORY PTY LTD +2

Electronic detection device and kit for influenza viruses and rhinoviruses

The invention relates to an electronic detection device and kit for influenza viruses and rhinoviruses and relates to the field of respiratory virus detection. The electronic detection device comprises a photoelectric detection module, a data processing module and colloidal gold detection test paper, wherein the colloidal gold test paper comprises a bottom lining, a nitrocellulose film, a gold padand a sample pad, the nitrocellulose film is fixed on the bottom lining, the gold pad is arranged between the nitrocellulose film and the sample pad, one side of the gold pad is partially overlappedwith the nitrocellulose film, the other side of the gold pad is partially overlapped with the sample pad, the nitrocellulose film coats a detection line and a quality control line close to one side ofthe gold pad, the detection line comprises a plurality of virus detection lines, the gold pad is made of mixture of multiple gold-labeled virus monoclonal antibodies, the photoelectric detection module is used for detecting color changes of the quality control line and the detection line, and the data processing module is used for judging whether influenza virus or rhinovirus infection exists ornot according to the color change detected by the photoelectric detection module. The electronic detection device is advantaged in that purposes of rapidness, convenient operation and low-cost detection can be achieved.
Owner:石家庄洹众生物科技有限公司

Protection against human rhinovirus infection

Methods, kits, and compositions are disclosed for vaccinating a human or animal against human rhinovirus infection. Also provided are methods of using a cotton rat model for identifying and testing vaccines and therapeutic agents that prevent or ameliorate human rhinovirus infection.
Owner:LOVELACE RESPIRATORY RES INST +1

Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus

The present invention provides ester derivatives of hydroxybenzoic acid for use in the treatment or prevention of a rhinovirus infection in a mammal wherein R represents a C1-10 alkyl group, X1, X2, X3, X4 and X5 independently represent —H or —OH and wherein at least one of X1, X2, X3, X4 and X5 is —OH.
Owner:ENZYMATICA

Application of Zukamu granules to preparation of drugs for resisting coxsakievirus and rhinovirus infection

The invention discloses Zukamu granules. The Zukamu granules are prepared from rhizome kaempferiae, nymphaea tetragona, mint, jujubes, chamomile, cordia dichotoma fruits, liquorice, hollyhock seeds, rheum officinale and pericarpium papaveris. The Zukamu granules are used for resisting coxsakievirus and / or rhinovirus infection. The Zukamu granules can effectively inhibit activity of coxsakievirus and rhinovirus, regulate abnormal constitution, clear heat, promote sweating and open orifices and is used for treating cold coughs, fever adiaphoresis, sore throat and nasal congestion.
Owner:新疆维吾尔药业有限责任公司 +1

Medicament for prevention of treatment of rhinovirus infection

ActiveUS20200397805A1Safe and effective HRV infectionPowder deliveryOrganic active ingredientsPowder InhalerPharmacology
The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.
Owner:MEDIZINISCHE UNIVET WIEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products